Shamburg News · 8-K filed Nov 4, 2026, 4:58 PM EST

Rallybio Stockholders Approve Avenzo Merger Proposals and Equity Plans; $13.90 Special Distribution Set

RLYB · Rallybio Corp

  • Shareholder vote
  • Material agreement
  • Dividend
  • Acquisition
  • Leadership change
  • Other event
  • Materiality: high

At its November 4, 2026 annual meeting, Rallybio stockholders approved the issuance of common stock to Avenzo securityholders under the merger agreement, a reverse split with a ratio range of 1-for-2 to 1-for-9, a name change to Avenzo Therapeutics, Inc., an increase in authorized shares to 500,000,000, the election of four Class II directors, Deloitte & Touche LLP as auditor, and the Avenzo 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. The company also disclosed a special cash distribution of $83.6 million, or $13.90 per share, with a November 5, 2026 record date and a November 9, 2026 expected ex-dividend date, and stated the merger is expected to close November 6, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 5.07, 8.01, 9.01, accession 0001193125-26-447550.

Written from the filing by Shamburg Markets. Figures are as reported by the company.